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Background: This study aims to examine the immunological parameters, focusing IL-10 productivity, in
prophylactic sublingual immunotherapy (SLIT) in asymptomatic subjects sensitized to Japanese cedar
pollen (JCP).
Methods: This study was conducted as part of a randomized, double-blind, placebo-controlled, multiple
center trial, and was performed for two consecutive pollen seasons in 2012 and 2013. The present results
were based only on our institution. We recruited 29 participants with speciﬁc IgE against JCP of at class 2
and higher levels without history of the pollinosis symptoms at the time of JCP scattering. The SLIT group
received standardized JCP extract for ﬁve months over the pollen season. We observed and judged
development of the symptoms in the pollen season. The percentage of IL-10 producing CD4þ T (Trl) cells,
B cells and monocytes were analyzed by ﬂow cytometry. JCP speciﬁc IgE and total IgE were also
measured.
Results: The ratio of development of cedar pollinosis was signiﬁcantly lower in the SLIT group compared
to the placebo group in 2013. In 2012, the percentage of circulating Tr1 cells and IL-10 producing
monocytes signiﬁcantly increased in the SLIT group. In 2013, the percentage of circulating Tr1 cells and
IL-10 producing B cells increased signiﬁcantly in the SLIT group. The percentage of circulating IL-10
producing monocytes signiﬁcantly decreased in the placebo group.
Conclusions: Prophylactic SLIT is effective for prevention of the development of pollinosis. Induction of
IL-10 producing T cells, B cells and monocytes is an important mechanism of SLIT for prevention of
pollinosis in asymptomatic but sensitized subjects.
Copyright © 2014, Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.Introduction
Japanese cedar pollinosis is an allergic disease speciﬁc to Japan
with a high prevalence estimated to be 26.5%, which has increased
by 10% over the past ten years.1 Seasonal allergic rhinitis induced by
cedar pollen takes a chronic course in the majority of middle-aged
patients.2 Remission rarely occurs, especially in the younger
generation.
Sublingual immunotherapy (SLIT) is safer than conventional
percutaneous antigen-speciﬁc immunotherapy, and is the onlylaryngology, Mie University
ie 514-8507, Japan.
K. Takeuchi).
ety of Allergology.
rgology. Production and hosting by Elstreatment which can completely cure the disease. It has been
shown that SLIT is effective and safe in the treatment of cedar
pollinosis by a randomized, placebo-controlled, double-blind
study.3
About 20% of asymptomatic subjects sensitized to this pollen
develop symptoms in the pollen scattering season.4 Thus, it is
important to prevent the development of pollinosis in these
asymptomatic, sensitized subjects. To determine whether SLIT can
prevent the development of pollinosis in sensitized subjects who
have no history of pollinosis, a randomized, placebo-controlled,
double blind trail was carried out over two pollinosis seasons in
2012 and 2013 in multiple facilities in Japan.
The mechanism of action of SLIT is not completely understood.
However, IL-10 is critical for the induction of speciﬁc Tcell tolerance
and the increase in lL-10 production by monocytes and T cells
during inﬂammatory responses or after SLIT may inﬂuence effectorevier B.V. All rights reserved.
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following speciﬁc immunotherapy causes anergy in peripheral T
cells, and regulates speciﬁc IgE and IgG4 production towards
normal IgG4-related immunity.5 Low IL-10 productivity by mono-
cytes and Tcells is closely related to sensitivity tomultiple allergens
and resistance to allergic diseases.6,7 Augmentation of constitutive
IL-10 production from the immune system is a potential thera-
peutic approach for allergic disorders. Thus we hypothesized that
IL-10 may play an important role in prophylactic SLIT for asymp-
tomatic sensitized subjects.
We also examined the ratio of speciﬁc IgE against total IgE (sIgE/
tIgE), because the evidence concerning the relationship between
this ratio and the efﬁcacy of SLIT is conﬂicting. Di Lorenzo et al.
reported that a high sIgE/tIgE ratio was associated with an effective
response in sublingual and subcutaneous immunotherapy in
monosensitized patients for the following allergens: grass, Parie-
taria judaica, Olea europea and house dust mite.8 On the other hand,
Fujimura et al. reported that the sIgE/tIgE ratio before treatment
correlated with the symptom-medication score in the SLIT group
and that patients with low sIgE/tIgE ratios were more responsive to
SLIT in treatment for Japanese pollinosis.9
We examined the immunological parameters, including IL-10
productivity, in prophylactic SLIT in asymptomatic subjects sensi-
tized to Japanese cedar pollen.
Methods
Study population
This studywas conducted as part of a randomized, double-blind,
placebo-controlled, multiple center trial in asymptomatic subjects
sensitized to Japanese cedar pollen (JCP), and the present results
were based only on our institution. The study was performed for
two pollen seasons from December 2011 to April 2013. We
recruited 29 participants with IgE speciﬁc to JCP of at class 2 and
higher without history of symptomatic pollinosis during JCP scat-
tering. Japanese cedar pollen-speciﬁc IgE titers and total IgE in the
serum were measured by CAP-FEIA (ﬂuorescent enzyme immu-
noassay) (Phadia, Tokyo, Japan) before the study. Participants who
were pregnant, breastfeeding or suffering from chronic rhinosi-
nusitis were excluded.
Ethics statement
This study adhered to the tenets of the Declaration of Helsinki,
and was approved by Mie University, Graduate School of Medicine
Ethical Committee (No. 2283). A written informed consent was
obtained from each subject before study.
Clinical protocols
The enrolled candidates were randomized into two groups by
age and the levels of Cry j 1-speciﬁc IgE. The SLIT group received
standardized JCP extract (Torii Pharmaceutical Co. Ltd., Tokyo,
Japan),10 and the placebo group received an inactive placebo. The
protocol consisted of treatments with graded courses of the extract
in 50% glycerol, followed by maintenance therapy.11 Brieﬂy, the
extracts were graded in two concentrations: 200 and 2000 JAU/ml.
From early December, the subjects received increasing doses
beginning with 0.2 ml of the 200 JAU/ml vial and increasing by
0.2 ml every second day until reaching the maintenance dose of
1.0 ml of the 2000 JAU/ml for two weeks. From the third week, they
received the maintenance dose of 1.0 ml of the 2000 JAU/ml daily
until the end of April in the following year. The vaccine was taken
sublingually, kept for 2 min without a retention reagent and thenswallowed. The subjects in the placebo group received inactive 50%
glycerol in saline.
Clinical symptoms and safety measurements
The subjects completed a pollinosis diary to record their nasal
and eye symptoms and their use of symptom-reducing drugs.
Development of the symptoms was determined on the basis of the
pollinosis diary and a nasal provocation test performed at the end
of April. The total amounts of pollen scattered from the Japanese
cedar and Japanese cypress (Chamaecyparis obtusa) in Tsu city, Mie
Prefecture, were 7031 and 16,578 grains/cm2 during 2012 and 2013
pollen seasons, respectively.
Total and antigen-speciﬁc immunoglobulin titer
The levels of Cry j 1-speciﬁc IgE and total IgE in serum were
measured by CAP-FEIA (ﬂuorescent enzyme immunoassay) (Pha-
dia, Tokyo, Japan).
Blood samples and PBMC culture
Peripheral blood was obtained from each subject before and
after treatment (December and April) each year. Peripheral blood
mononuclear cells (PBMC) were isolated from 10 ml of heparinized
venous blood by density gradient centrifugation using Ficoll 1077
(Sigma, St. Louis, MO, USA). PBMC were cultured in RPMI 1640
medium (Nikken Bio Medical Laboratory, Kyoto, Japan) containing
L-glutamine supplemented with 100 U/mL penicillin, 100 U/mL
streptomycin (Invitrogen, Carlsbad, CA, USA) and l0% Human AB
serum (Gemini Bio-Products, West Sacramento, CA, USA). Cells
were plated onto 24-well tissue culture plates at a density of
2  106 cells/mL/well and were incubated with 10 JAU of Cry j1
(Torii, Tokyo, Japan) for 8 h at 37 C in an atmosphere of 5% CO2.
Endotoxin level was conﬁrmed to be less than 0.1 ng/mg (1 EU/mg) of
the protein in Cry j1.
IL-10 staining in T cells, B cells and monocytes
After 8 h cultivation with antigens, PBMC were collected and
incubatedwith PE-conjugated IL-10 secretion assay kit according to
the manufacturer's instructions (Miltenyi Biotec, Auburn, CA, USA).
Cells were also co-stained with anti-CD4-FITC and CD19-PECy5
antibodies, or anti-CD14-FITC antibody (eBioscience, Sam Diego,
CA, USA). The percentage of IL-10 producing CD4þ T cells, B cells
and monocytes were determined using an Accuri C6 ﬂow cytom-
eter (Becton Dickinson, Mansﬁeld, MA).
Statistical analysis
Two-group comparisons were performed using a Wilcoxon test
or ManneWhitney U-test to determine the signiﬁcance of differ-
ences, or using an unpaired t-test as indicated. A p value of less than
0.05 was considered statistically signiﬁcant.
Results
Clinical effects
Two subjects withdrew during the course of the study. The
demographic characteristics of the 27 subjects before treatment are
shown in Table 1. Clinical data from participants in 2012 and 2013
are shown in Table 2. As shown in Table 1, mean age of placebo
group is higher compared to that of SLIT group; however, IL-10
production form T cells or monocytes is unchanged among
Table 2
Clinical data of participants in 2012 and 2013.
Group 2012 2013 P-value
Number 17 17
SLIT/placebo 9/8 7/10
Male/Female 7/10 9/8 N.S.y
Age (mean, range) 34.2 (21e52) 34.6 (18e52) N.S.z
Total IgE (mean, range) 121 (22.5e548) 298 (5.0e1310) N.S.z
Speciﬁc IgEx (mean, range) 11.7 (1.2e84.7) 10.2 (0.7e49.3) N.S.z
Class (mean, range) 2.8 (2e5) 2.8 (2e4) N.S.z
Ratio of sIgE/tIgE
(mean, range)
0.15 (0.0061e0.49) 0.11 (0.0048e0.63) N.S.z
y Yates 2  2 Chi-squared test.
z Student t-test.
x Speciﬁc IgE to Japanese cedar pollen; ImmunoCAP raw value [UA/ml], mean.
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participated in the study. Seven of the participants in 2012
continued to participate in the second year. These seven subjects
did not develop symptoms in the ﬁrst year.
In 2012, four of the SLIT group and one of the placebo group
developed symptoms. There was no signiﬁcant difference in the
ratio of symptom development between the two groups in 2012. In
2013, seven of the placebo group but none of the SLIT group
developed symptoms. The ratio of the development of pollinosis in
the SLIT group was signiﬁcantly lower than that of the placebo
group in 2013 (p ¼ 0.0098, Fisher's exact test). To clarify the
possible factors inﬂuencing clinical effects, we compared age, sex
ratio and sIgE/tIgE ratio between 2012 and 2013. However, there
was no signiﬁcant difference in these factors in the two years
(Table 2). We also compared these factors between the SLIT group
and the placebo group in each year, but statistical signiﬁcance was
not detected (data not shown).
Prognostic biomarker for clinical effects
A comparison of the ratio of sIgE/tIgE in the preseason period is
shown in Fig. 1. The ratio of sIgE/tIgE in the preseasonwas higher in
those who developed symptoms in 2013 (B), but not in 2012 (A). In
the SLIT group, the sIgE/tIgE ratio in the preseason period was
signiﬁcantly higher in those who developed symptoms (C). In the
placebo group, there was no signiﬁcant difference in the ratio be-
tween the subjects developed pollinosis and those did not (D).
IL-10 production in T cells, B cells and monocytes during SLIT
In 2012, it was impossible for us to collect blood from one
subject in each group due to their personal reasons. In 2013, one
subject as the ﬁrst year trial in the SLITgroup and another subject as
the second year trial in the placebo group were unable to come to
the hospital for the blood collection in the postseason due to their
personal reasons. Thus, we were unable to obtain blood samples
from four subjects in total.
The percentage of IL-10-producing T cells, B cells andmonocytes
in 2012 is shown in Fig. 2. The percentage of circulating Tr1 cells (IL-
10þCD4þ T cells/CD4þ T cells) and IL-10 producing monocytes (IL-
10þCD14þcells/CD14þcells) signiﬁcantly increased in the SLIT group
(p ¼ 0.0117, Tr1 and p ¼ 0.0117, monocyte, respectively). However,
the number of IL-10 producing B cells (IL-10þCD19þcells/
CD19þcells) remained unchanged. The results for the 2013 season
are shown in Fig. 3. The percentages of circulating Tr1 and IL-10
producing B cells signiﬁcantly increased in the SLIT group
(p ¼ 0.0277, Tr1 and p ¼ 0.0277, B cell, respectively). On the other
hand, the percentage of circulating IL-10 producing monocytes
signiﬁcantly decreased in the placebo group (p ¼ 0.0077).Table 1
Clinical data of 27 participants at the start of the study.
Group SLIT Placebo P-value
Number 13 14
Male/Female 5/8 7/7 N.S.y
Age (mean, range) 27.8 (18e47) 36.1 (19e52) p ¼ 0.03z
Total IgE (mean, range) 214 (23e823) 222 (5e1310) N.S.z
Speciﬁc IgEx
(mean, range)
13.9 (0.74e84.7) 9.64 (0.88e49.3) N.S.z
Class (mean, range) 2.8 (2e5) 2.6 (2e4) N.S.z
Ratio of sIgE/tIgE
(mean, range)
0.11 (0.0049e0.44) 0.15 (0.00061e0.63) N.S.z
y Yates 2  2 Chi-squared test.
z Student t-test.
x Speciﬁc IgE to Japanese cedar pollen; ImmunoCAP raw value [UA/ml], mean.The enrolled patients in 2013 were divided into two categories:
the subjects with ﬁrst year trial and the second year trial. Therefor
the data of IL-10-producing T cells, B cells and monocytes in 2013
was calculated separately. As shown in Fig. 4A, nine subjects had
participated as the ﬁrst year trial. Three subjects in the SLIT group
and six subjects in the placebo group are shown. IL-10 producing
monocytes were statistically decreased in placebo group at the post
season. The other hand, six subjects had participated as the second
year trial. Three subjects in the SLIT group and three subjects in the
placebo group are shown. Although the signiﬁcant difference was
undetected, the actual percentage of Tr1 and IL-10 producing B cells
seems to be higher in the second-year trial compared to the ﬁrst-
year trial (Fig. 4B).Discussion
To our knowledge, this is the ﬁrst report examining the per-
centage of circulating IL-10 producing T cells, B cells and monocytes
in prophylactic SLIT treatment in those who are sensitized to pollen
but do not develop pollinosis. A signiﬁcant increase in the per-
centage of Tr1 in the SLIT group was observed in both years of the
study. The up-regulation of Tr1 cells may play a critical role in
speciﬁc immunotherapy and be a useful marker of successful
response in allergic rhinitis patients. It has been reported that the
levels of allergen-speciﬁc Tr1 cells, IgG4 and allergen-induced IL-10
synthesis from PBMC cultures were signiﬁcantly increased after
cluster speciﬁc immunotherapy in Der p-sensitized children with
allergic rhinitis compared with baseline levels, with a signiﬁcant
correlation between increased levels of Tr1 cells and improvement
in nasal symptoms.12
A signiﬁcant increase in the circulating IL-10 producing B cells in
the SLIT group was observed only in the 2013 season. IL-10-
producing regulatory B cells suppress immune responses, and the
lack of these cells leads to exacerbated symptoms. According to van
de Veen et al., IL-10 producing B cells suppressed antigen-speciﬁc
CD4þ T-cell proliferation.13 B cells speciﬁc for the major bee
venom allergen phospholipase A2 (PLA) isolated from non-allergic
beekeepers show increased expression of IL-10 and IgG4. IgG4 is a
blocking antibody isotype with anti-inﬂammatory potential that is
induced in human high-dose antigen tolerance.13 Furthermore, the
frequency of IL-10þ PLA speciﬁc B cells increased in allergic patients
receiving allergen-speciﬁc immunotherapy.13 IL-10-producing B
cells, also known as regulatory B cells (B regs), also play a key role in
controlling autoimmunity. Mice lacking endogenous IL-10-
producing regulatory B cells developed exacerbated disease and
presented with a decrease in regulatory T cells.14
Monocyte is a major source of IL-10 in PBMC, and is a key cells
for IL-10 mediated immunomodulation. The changes in percentage
of IL-10 producing monocytes were different between the two
Fig. 1. Comparison of the ratio of sIgE/tIgE in the preseason period. The ratio of sIgE/tIgE in the preseason was higher in those who developed symptoms in 2013 (B), but not in 2012
(A). In the SLIT group, the sIgE/tIgE ratio in the preseason period was signiﬁcantly higher in those who developed symptoms (C). In the placebo group, there was no signiﬁcant
difference in the ratio between those who developed pollinosis and those who did not (D). When the subjects received SLIT for two years, only the data in the ﬁrst year was adopted.
The graph shows the mean ± standard deviation. The comparison was made using ManneWhitney U-test.
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signiﬁcantly increased in the SLIT group. On the other hand, the
percentage of IL-10 producing monocytes signiﬁcantly decreased in
the placebo group in 2013. Therefore a decrease in the percentageFig. 2. The percentage of IL-10-producing T cells, B cells and monocytes in 2012. The percen
the SLIT group. The percentage of circulating IL-10 producing monocytes (IL-10þCD14þcell
producing B cells (IL-10þCD19þcells/CD19þcells) remained unchanged. (n ¼ 8 in SLIT, n ¼
values was performed using a Wilcoxon test. The comparison between the SLIT group andof IL-10 producing monocytes was prevented with the SLIT proto-
col. Pollinosis developed in 70% of the placebo group but none of
the SLIT group in 2013. The percentage of IL-10 producing mono-
cytes was signiﬁcantly higher in healthy subjects than in thosetage of circulating Tr1 (IL-10þCD4þ T cells/CD4þ T cells) cells signiﬁcantly increased in
s/CD14þcells) signiﬁcantly increased in the SLIT group. However, the number of IL-10
7 in placebo) The comparison between the pre-season values and the post-season
the placebo group was done using the ManneWhitney U-test.
Fig. 3. The percentage of IL-10-producing T cells, B cells and monocytes in 2013. The percentage of circulating Tr1 (IL-10þCD4þ T cells/CD4þ T cells) cells and IL-10 producing B cells
(IL-10þCD19þcells/CD19þcells) signiﬁcantly increased in the SLIT group. The percentage of circulating IL-10 producing monocytes (IL-10þCD4þcells/CD14þcells) signiﬁcantly
decreased in the placebo group. (n ¼ 6 in SLIT, n ¼ 9 in placebo) The comparison between the pre-season values and the post-season values was performed using a Wilcoxon test.
The comparison between the SLIT group and the placebo group was performed using the ManneWhitney U-test.
Fig. 4. The percentage of IL-10-producing T cells, B cells and monocytes in 2013. (A) This ﬁgure shows 10 subjects who have participated in the ﬁrst year. Three subjects in the SLIT
group and six subjects in the placebo group are shown. IL-10 producing monocytes were statistically decreased in placebo group at the post season. (B) This ﬁgure shows 7 subjects
who have participated in two consecutive years. Three subjects in the SLIT group and three subjects in the placebo group are shown. The signiﬁcant difference was undetected. The
comparison between pre-season values and the post-season values was performed using a Wilcoxon test. The comparison between the SLIT group and placebo group was per-
formed using the ManneWhitney's U-test.
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is assumed that decreased IL-10 production bymonocytes is closely
related to becoming symptomatic. On the other hand, SLIT pre-
vented subjects from becoming symptomatic by up-regulating the
IL-10 productivity. Monocytes recognize antigens via Toll like re-
ceptors, digest antigen with intrinsic enzyme, and some pop-
ulations such as CD14þCD16þ monocytes present antigens
combined with expression of MHC class II like antigen presenting
cells.15
The reason for the difference in the clinical efﬁcacy of SLIT and
the percentage of IL-10 producing cells between the two years is
unclear. In 2012, nearly half of subjects received SLIT treatment
developed the symptoms, although IL-10 producing T cells signiﬁ-
cantly increased in the SLIT group. Among patients with symp-
tomatic pollinosis treated by SLIT, some patients do not show the
efﬁcacy, although Tr1 ratio is increased. In the same way, in 2012
we speculate increased level of Tr1 induced by SLIT was not enough
to suppress nasal allergy symptoms. The difference in the exposed
pollen amounts might have some effects to the results. Exposure to
larger amounts of pollen in 2013 might have helped switching and
expansion of IL-10 producing cells. It is known that high dose bee
venom exposure in beekeepers by natural bee stings represents a
model to understand mechanisms of T cell tolerance to allergens in
healthy individuals.16 Rapid switch and expansion of IL-10-
producing Tr1 cells and the use of multiple suppressive factors
represent essential mechanisms in immune tolerance to a high
dose of allergens in non-allergic individuals.16
The subjects who developed pollinosis in 2012 did not partici-
pate in the study the next year. Thus, the study in 2013 comprised
new subjects (n ¼ 10) and those who did not develop pollinosis in
2012 (n¼ 7). This might have inﬂuenced the clinical efﬁcacy of SLIT
and the percentage of the IL-10 producing cells.
Those who developed pollinosis in the SLIT group had a signif-
icantly higher sIgE/tIgE ratiowhich supports the results reported by
Fujimuara et al.9 We speculate that effector cells with a low speciﬁc
IgE level are less likely to be activated by antigen crosslinking or are
more susceptible to downregulation by IL-10 producing cells than
those with a high speciﬁc IgE level. The symptoms of patients with
a low sIgE/tIgE ratio may be more easily attenuated by suboptimal
potentiation of IL-10 producing cells by SLIT.9 A high sIgE/tIgE ratio
before the season may be predictive of development of pollinosis.
Uekusa et al.4 examined 33 adults who were sensitized to JCP but
who had not developed symptoms and found that the sIgE/tIgE was
signiﬁcantly higher before the season in the subjects who devel-
oped pollinosis.
A limitation of the present study is the small number of samples.
Further study is necessary to perform the analysis using a larger
number of subjects.
Prophylactic SLIT is effective in preventing development of
pollinosis. IL-10 producing T cells, B cells and monocytes play
important roles in the mechanism of SLIT for the prevention of
pollinosis in asymptomatic and sensitized subjects.
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